SACHDNC Meeting January 26/27, 2012 Nomination and Prioritization Workgroup Report on 22q11.2 Deletion Syndrome (22q11.2DS; DiGeorge Syndrome, DGS-1) Dietrich.

Slides:

Advertisements

Similar presentations

Surveillance & Tracking for EHDDI in WA Debra Lochner Doyle, MS, CGC February 2003.

Advertisements

Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.

SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.

Care Management for Children with Special Health Care Needs: Addressing and Financing an Unmet Need May 30, 2007 April 17, 2006.

Family Centered Approach Hussain Ali Maseeh, Psy.D. Director of SEDIC.

April 1 st, 2013 Heart Failure Education Series David N. Edwards, M.D. Ph.D. F.A.C.C. Advanced Heart Care, PA The Heart Hospital Baylor Plano.

Ad Hoc Committee Update: Impact of NCAA Sickle Cell Trait Mandate Alexis Thompson January 16, 2014.

National Center for Environmental Health Centers for Disease Control and Prevention Carla Cuthbert, PhD, FACMG, FCCMG Chief, Newborn Screening and Molecular.

Severe combined immune deficiency in Nablus Omar Abuzaitoun, MD.

Confirmatory Testing Considerations

Draft manuscript: “Implementing Point-of-Care Newborn Screening” From the SACHDNC Follow-up & Treatment Sub-committee 1/27/2012 Nancy S. Green, MD Associate.

Treuman Katz Center for Pediatric Bioethics Conference Newborn Screening: The Future Revolution Beth A. Tarini, MD, MS Assistant Professor Child.

Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.

In Collaboration with NewSTEPs: Data collection efforts at the national level for newborn screening quality improvement Marci K Sontag, PhD NewSTEPs (Newborn.

The National Coordinating Center for the Regional Genetic and Newborn Screening Service Collaboratives (NCC/RC System) ACTions Matter: A Candid Conversation.

Nomination and Prioritization Reports: MPS I and Pompe Disease Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of.

Molecular LDT in Newborn Screening Laboratories

Definition of a Consumer One that consumes, especially one that acquires goods or services for direct use or ownership rather than for resale or use in.

Breast Cancer Risk and Risk Assessment Models

Genetic Testing for Wilson Disease Melissa Dempsey, M.S., CGC The University of Chicago Genetic Services Laboratory July 17, 2010.

Jennifer Ivanovich, MS Washington University School of Medicine St. Louis, MO.

National Center for Environmental Health Centers for Disease Control and Prevention Suzanne Cordovado, Ph.D. Team Lead, Molecular Quality Improvement Program.

Secretary’s Advisory Committee on Heritable Disorders of Newborns and Children September 22, 2011 Newborn Screening Translational Research Network (NBSTRN)

Role of CBR Strategy on disability prevention and control Deepak Raj Sapkota Country Director Karuna Foundation Nepal.

Alport Syndrome Genetics and Diagnosis Martin Gregory, MD, PhD Professor of Medicine University of Utah Nothing to disclose.

CHILD HEALTH PROFILE FOR CHILDREN WITH SPECIAL HEALTH CARE NEEDS AAP Annual Meeting Council on Clinical Information Technology-October 28,2007 Carmen B.

A Review of the Committee Nomination and Review Process Nancy S. Green, MD Associate Dean for Clinical Research Operations Associate Professor of Clinical.

Update from the Cost Analysis Workgroup Lisa A. Prosser, Ph.D., M.S. March 14, 2014.

Pilot Studies Work Group Jeffrey Botkin, MD, MPH.

Newborn Screening Translational Research Network Coordinating Center Duane Alexander, M.D. Director, Eunice Kennedy Shriver National Institute of Child.

Background The disease first appeared in the medical literature when endocrinologists Prader, Labhart, and Willi published a report describing an unusual.

Carisa Sanborn and Nikita Meshwani. PATIENTS  People who want to learn about their birth defects  Women who want to know if their children will have.

Proposed Changes to Advisory Committee Processes Sara Copeland, MD Designated Federal Official Secretary’s Advisory Committee on Heritable Disorders in.

2008© COPYRIGHT Thrombosis and Hemostasis Centers Research and Prevention Network Centers for Disease Control & Prevention Thomas L. Ortel, M.D., Ph.D.

Ethical and Regulatory Considerations in Research using Residual Specimens Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics and Medical Ethics Associate.

Evidence Review Group: Past to Present James M. Perrin, MD Professor of Pediatrics, Harvard Medical School MGH Center for Child and Adolescent Health Policy.

The NCC is funded by U22MC24100, awarded as a cooperative agreement between the Maternal and Child Health Bureau/Health Resources and Services Administration,

Rotavirus Vaccine: use in Wisconsin, effects on primary care visits, hospitalizations, and laboratory detections Jonathan L. Temte, MD/PhD Associate Professor.

Newborn Screening for Severe Combined Immune Deficiency: Advocacy, Challenges, and Next Steps Marcia Boyle President and Founder Immune Deficiency Foundation.

February 2009 Bethesda, MD.  NNSGRC  GEMS database up – links being established  Regional Collaboratives  50+ educational & training programs  Genetic.

Recommendation to ACHDNC for Newborn Screening for X-linked Adrenoleukodystrophy Fred Lorey, Ph.D. Don Bailey, Ph.D. Liaisons to the Condition Review Workgroup.

Regional Genetics Collaboratives: A Hidden EHDI Resource Penny Hatcher, MSN, DrPH Nancy Vanderburg, BSN, PHN Minnesota Department of Health St. Paul, Minnesota.

Call in number: Conference code: NBSTRN SCID National Call October 28, 2011.

Wisconsin Genomics Initiative W isconsin M edical R esearch T riangle Wisconsin Medical Discovery Triangle.

Follow up and Treatment Subcommittee January 26, 2012 Report Coleen Boyle, PhD, MS.

Update on SACHDNC Administrative Processes Sara Copeland, MD Chief, Genetics Services Branch Designated Federal Officer Secretary’s Advisory Committee.

Pompe Disease Evidence Evaluation Michael Watson, PhD, on behalf of Piero Rinaldo, MD, PhD, and the Decision-Making Workgroup October 1, 2008.

I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.

Recommendation Methods Advisory Committee on Heritable Disorders and Genetic Diseases of Newborns and Children Ned Calonge, M.D., M.P.H.

Call in number: Conference code: NBSTRN SCID National Call November 18, 2011.

Understanding Genetic Testing

Inherited Thrombophilia Testing as Observed at a Reference Laboratory Brian Jackson, MD, MS Medical Director of Informatics.

Genetic disorders can be due to any of the following factors: A. Monogenetic Disorders: Caused by a mutation in a single gene 1. Autosomal recessive alleles:

TEXAS NEWBORN SCREEN PRESENTED BY: SHAYNA BAUMAN & ROSA CARRANZA UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ADVANCED NEONATAL HEALTH ASSESSMENT GNRS.

TREC SCREENING. Characteristics of Disorders Characteristics of Test Well characterized pathogenesis Affects a significant number of infants Undetectable.

GP LABORATORY MEDICINE UPDATE MEETING Investigation of lymphopaenia and neutropenia in Primary Care Huw Roddie.

Genetics of Cardiomyopathy Affairs of the Heart: Living with Inherited Cardiomyopathy February 20, 2016 Kyla Dunn, MS, LCGC Cardiovascular Genetic Counselor.

Pulse Oximetry Screening for Critical Congenital Heart Disease (CCHD): The Wisconsin Experience Region IV Genetics Meeting September 11, 2012 Sharon Fleischfresser.

Why? 1 in 100 newborns have congenital heart defects 25% of all CHD are critical (CCHD) requiring intervention in the.

Laboratory Medicine Practice Guidelines (LMPG) Evidence Based Practice for Point of Care Testing.

Prevent Disease – Promote Wellness – Improve Quality of Life Michigan update for T Cell Receptor Excision Circle (TREC) analysis for detection of primary.

MCADD, caused by mutation in the ACADM gene is the most common disorder of fatty acid  - oxidation. Treatment is very successfully if started before symptoms.

22q11.2 deletion and other Microdeletion Syndromes Michael A. Kayser, D.O., FACMG Director of Medical Services Cancer Treatment Centers of America at Southwestern.

Hereditary Cancer Predisposition: Updates in Genetic Testing

Clinical, immunological and pathological features of severe combined immunodeficiency (SCID) at PGIMER, Chandigarh Amit Rawat¹, Sagar Bhattad¹, Deepti.

Christopher J. Klein, MD, Tatiana M. Foroud, PhD

Newborn Screening: Achieving Timeliness

Development and Validation of HealthImpactTM: An Incident Diabetes Prediction Model Based on Administrative Data Rozalina G. McCoy, M.D.1, Vijay S. Nori,

Christopher J. Klein, MD, Tatiana M. Foroud, PhD

Levine RA, DO. Miladinovic B, PhD. Nardell K, MD. Galas J, MD

Presentation transcript:

SACHDNC Meeting January 26/27, 2012 Nomination and Prioritization Workgroup Report on 22q11.2 Deletion Syndrome (22q11.2DS; DiGeorge Syndrome, DGS-1) Dietrich Matern, MD, FACMG Biochemical Genetics Laboratory Mayo Clinic, Rochester, MN

SACHDNC Meeting January 26/27, 2012 Nomination of 22q11.2DS Proponents: - John Routes, MD (primary contact) and James Verbsky, MD, PhD Medical College of Wisconsin, Milwaukee, WI - Kathleen Sullivan, MD and Donna McDonald-McGinn, MS, CGC Children’s Hospital of Philadelphia, PA Supporting Organizations: - Jeffrey Modell Foundation - Immune Deficiency Foundation - International 22q11.2DS Foundation - Dempster Family Foundation

SACHDNC Meeting January 26/27, 2012 Condition: 22q11.2 Deletion Syndrome (22q11.2DS; DiGeorge syndrome, Velocardiofacial syndrome, etc.) Genetics: autosomal dominant >90% de novo deletion <10% inherited from parent Prevalence: 1 in ca. 4,000 live births; panethnic Phenotype: variable (mild to severe) intrafamililal variability as well Treatment: symptomatic Nomination of 22q11.2DS for NBS

SACHDNC Meeting January 26/27, q11.2DS Clinical Concerns over Time McDonald-McGinn DM & Sullivan KE. Medicine 2011;90: 1-18

More significant issues relate to management of patients once the diagnosis is established. The varied presentations and the varied phenotypic constellations mandate that each patient have a nearly unique management strategy. Nevertheless, coordinated care and comprehensive approaches are possible. The promise, and the possibility of improved interventions for neuropsychiatric needs could lead to enhanced adult function. SACHDNC Meeting January 26/27, 2012 McDonald-McGinn DM & Sullivan KE. Medicine 2011;90: q11.2DS Treatment

Proposed Method: –Multiplex quantitative RT-PCR for TBX1 copy number –1/8-inch (3.2 mm) punch/test Overlap with existing NBS methods? SACHDNC Meeting January 26/27, 2012 NBS for 22q11.2DS

SACHDNC Meeting January 26/27, 2012 Nomination of 22q11.2DS CCHD

Proposed Method: –Multiplex quantitative RT-PCR for TBX1 copy number –1/8-inch (3.2 mm) punch/test Overlap with existing NBS methods? –Pulseoximetry for CCHD: At least 50% of patients with 22q11.2DS have a cyanotic heart defect –SCID screening: SACHDNC Meeting January 26/27, 2012 NBS for 22q11.2DS

SACHDNC Meeting January 26/27, cases of 22q11.2DS CASES by CONDITION Total Number of Cases: 41 (1/23/2012)

Proposed Method: –Multiplex quantitative RT-PCR for TBX1 copy number –1/8-inch (3.2 mm) punch/test Overlap with existing NBS methods? –Pulseoximetry for CCHD: At least 50% of patients with 22q11.2DS have a cyanotic heart defect –SCID screening: 67% of 22q11.2DS have T-cell lymphopenia SACHDNC Meeting January 26/27, 2012 NBS for 22q11.2DS

Proposed Method: –Multiplex quantitative RT-PCR for TBX1 copy number –DNA –1/8-inch (3.2 mm) blood spot punch/test SCID screening: –Quantitative RT-PCR for T-cell receptor excision circle (TRECs) analysis –DNA –1/8-inch (3.2 mm) blood spot punch/test SACHDNC Meeting January 26/27, 2012 NBS for 22q11.2DS

Newborn screening programs: should 22q11 deletion syndrome be added? Bales AM, Zaleski CA, McPherson EW. Genet Med. 2010;12: SACHDNC Meeting January 26/27, 2012

Newborn screening programs: should 22q11 deletion syndrome be added? Bales AM, Zaleski CA, McPherson EW. Genet Med. 2010;12:135-44

SACHDNC Meeting January 26/27, 2012 Newborn screening programs: should 22q11 deletion syndrome be added? Bales AM, Zaleski CA, McPherson EW. Genet Med. 2010;12:135-44

SACHDNC Meeting January 26/27, 2012 Newborn screening programs: should 22q11 deletion syndrome be added? Bales AM, Zaleski CA, McPherson EW. Genet Med. 2010;12:135-44

No prospective study performed to date –How well does the test perform (false positive rate, false negative rate, positive predictive value, specificity, sensitivity)? –Will it detect individuals with 22q11.2 duplications (which can be of NO clinical consequence)? Significant number of cases expected to be identified through NBS for SCID and CCHD Must other presentations of 22q11.2DS be detected? Limited number of experienced, multi-center clinical centers Proposal is for 1 DBS punch for 1 condition Potential waste of specimen; consider combining with NBS for other condition(s), such as SCID, to save DBS SACHDNC Meeting January 26/27, 2012 NBS for 22q11.2DS

Do not initiate External Evidence Review yet Suggest to proponents/NBS community to conduct a prospective NBS study for 22q11/2DS to determine –test performance metrics; –if current NBS for SCID and CCHD is sufficient to detect clinically significant 22q11.2DS cases; –if testing for 22q11.2DS could be multiplexed with other DNA based NBS assays, in particular SCID; –Development of ACTion and algorithms ( Recommend to NBS programs that already test for SCID to participate in Region 4 SCID project. SACHDNC Meeting January 26/27, 2012 Nomination of 22q11.2DS for NBS - Recommendation to SACHDNC -